Loading the section
Prices delayed by 15 minutes
The series is stated in the current share scale after splits; dividends are not included in the price
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| September 15, 2026 | 42.73 | 43.00 | 42.40 | 42.53 | 9m |
| September 14, 2026 | 43.66 | 43.71 | 43.07 | 43.45 | 7m |
| September 11, 2026 | 43.20 | 43.50 | 42.72 | 43.07 | 11m |
| September 10, 2026 | 44.60 | 44.82 |
Based on reports through December 31, 2025
Novo Nordisk A/S (NVO) is a public company in the healthcare sector. Its common stock trade on NYSE.
Over the trailing twelve months as reported to 2025-12-31, revenue was 309.1bn, net income was 102.4bn.
This summary is compiled automatically from SEC filings and exchange data.
Address:NOVO ALLE DK 2880, BAGSVAERD DENMARK, 00000, DK
| 1.2bn |
| PFEPfizer, Inc. | 27.66 | +0.71 % | 992m |
| ABTAbbott Laboratories | 102.56 | +19.50 % | 848m |
| VRTXVertex Pharmaceuticals Incorporated | 514.98 | +33.50 % | 582m |
| BMYBristol-Myers Squibb Company | 62.76 | −1.32 % | 575m |
| 44.01 |
| 44.01 |
| 7m |
| September 09, 2026 | 45.00 | 45.40 | 44.52 | 44.56 | 9m |
| September 08, 2026 | 45.58 | 45.91 | 45.15 | 45.16 | 10m |
| September 04, 2026 | 46.35 | 46.74 | 46.04 | 46.60 | 6m |
| September 03, 2026 | 47.99 | 48.00 | 46.57 | 47.51 | 9m |
| September 02, 2026 | 46.05 | 47.01 | 45.91 | 46.77 | 14m |
| September 01, 2026 | 45.80 | 46.16 | 45.07 | 45.12 | 9m |
| August 31, 2026 | 45.28 | 45.61 | 44.95 | 45.33 | 8m |
| August 28, 2026 | 46.17 | 46.21 | 45.41 | 45.61 | 8m |
| August 27, 2026 | 45.97 | 46.33 | 45.70 | 46.26 | 13m |
| August 26, 2026 | 47.80 | 48.04 | 46.87 | 47.19 | 9m |
| August 25, 2026 | 47.84 | 48.66 | 47.56 | 48.66 | 16m |
| August 24, 2026 | 47.09 | 47.30 | 46.57 | 46.92 | 10m |
| August 21, 2026 | 46.35 | 47.17 | 46.34 | 46.74 | 11m |
| August 20, 2026 | 46.89 | 46.90 | 46.11 | 46.14 | 10m |
| August 19, 2026 | 46.01 | 47.20 | 45.84 | 46.48 | 20m |
| August 18, 2026 | 44.91 | 46.07 | 44.76 | 45.71 | 12m |